Jon A Oyer
Overview
Explore the profile of Jon A Oyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li J, Hlavka-Zhang J, Shrimp J, Piper C, Dupere-Richer D, Roth J, et al.
Cancer Discov
. 2021 Aug;
12(1):186-203.
PMID: 34417224
Mutations in epigenetic regulators are common in relapsed pediatric acute lymphoblastic leukemia (ALL). Here, we uncovered the mechanism underlying the relapse of ALL driven by an activating mutation of the...
2.
Bennett R, Bele A, Small E, Will C, Nabet B, Oyer J, et al.
Cancer Discov
. 2019 Jul;
9(10):1438-1451.
PMID: 31337617
By examination of the cancer genomics database, we identified a new set of mutations in core histones that frequently recur in cancer patient samples and are predicted to disrupt nucleosome...
3.
Swaroop A, Oyer J, Will C, Huang X, Yu W, Troche C, et al.
Oncogene
. 2018 Sep;
38(5):671-686.
PMID: 30171259
NSD2, a histone methyltransferase specific for methylation of histone 3 lysine 36 (H3K36), exhibits a glutamic acid to lysine mutation at residue 1099 (E1099K) in childhood acute lymphocytic leukemia (ALL),...
4.
Comess K, McLoughlin S, Oyer J, Richardson P, Stockmann H, Vasudevan A, et al.
J Med Chem
. 2018 May;
61(19):8504-8535.
PMID: 29718665
Small-molecule (SM) leads in the early drug discovery pipeline are progressed primarily based on potency against the intended target(s) and selectivity against a very narrow slice of the proteome. So,...
5.
McGann J, Oyer J, Garg S, Yao H, Liu J, Feng X, et al.
Elife
. 2014 Sep;
3:e04235.
PMID: 25250711
The bivalent hypothesis posits that genes encoding developmental regulators required for early lineage decisions are poised in stem/progenitor cells by the balance between a repressor histone modification (H3K27me3), mediated by...
6.
Nesti E, Corson G, McCleskey M, Oyer J, Mandel G
Proc Natl Acad Sci U S A
. 2014 Sep;
111(37):E3929-36.
PMID: 25197063
The repressor element 1 (RE1) silencing transcription factor (REST) in stem cells represses hundreds of genes essential to neuronal function. During neurogenesis, REST is degraded in neural progenitors to promote...
7.
Belcik J, Qi Y, Kaufmann B, Xie A, Bullens S, Morgan T, et al.
J Am Coll Cardiol
. 2012 Jun;
60(7):618-25.
PMID: 22703929
Objectives: This study sought to evaluate the contribution of microvascular functional rarefaction and changes in vascular mechanical properties to the development of hypertension and secondary ventricular remodeling that occurs with...
8.
Oyer J, Yates P, Godsey S, Turker M
Mutat Res
. 2010 Nov;
706(1-2):21-7.
PMID: 21035468
A hallmark of aberrant DNA methylation-associated silencing is reversibility. However, long-term stability of reactivated promoters has not been explored. To examine this issue, spontaneous reactivant clones were isolated from mouse...
9.
Oyer J, Chu A, Brar S, Turker M
PLoS One
. 2009 Mar;
4(3):e4832.
PMID: 19279688
Background: Aberrant epigenetic silencing plays a major role in cancer formation by inactivating tumor suppressor genes. While the endpoints of aberrant silencing are known, i.e., promoter region DNA methylation and...